Aeterna Zentaris (AEZS) – Company Press Releases
-
Ceapro Receives Final Court Approval for Merger with Aeterna Zentaris
-
Aeterna Zentaris Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Completion of Enrollment in Ongoing Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone
-
Aeterna Zentaris and Ceapro Merger Approved by Securityholders at Special Meetings
-
Leading Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders Vote FOR the Arrangement Agreement to Approve the Merger of Equals to Create a Diversified Biopharmac
-
Aeterna Zentaris Issues Letter to Shareholders and Management Proxy Circular Ahead of Special Meeting of Shareholders to Approve Merger of Equals with Ceapro
-
Aeterna Zentaris and Ceapro Announce Merger of Equals to Create a Diversified Biopharmaceutical Company
-
Aeterna Zentaris Reports Third Quarter 2023 Financial Results
-
Aeterna Zentaris to Participate at the Virtual Investor Ask the CEO Conference
-
Aeterna Zentaris to Present at the H.C. Wainwright 25th Annual Global Investment Conference
-
Aeterna Zentaris Reports Second Quarter 2023 Financial Results
-
Aeterna Zentaris Outlines Progress on Development Pipeline Programs and Provides Corporate Update
-
Aeterna Zentaris to Participate in the Virtual Investor Summer Spotlight Series
-
Aeterna Zentaris Announces Results of Virtual 2023 Meeting of Shareholders
-
Aeterna Zentaris Announces Virtual 2023 Meeting of Shareholders
-
Aeterna Zentaris Reports First Quarter 2023 Financial Results
-
Aeterna Zentaris Provides Update on Macrilen® (Macimorelin), Reiterates Advancement of Pediatric DETECT Trial
-
Aeterna Zentaris Reports Fourth Quarter and Full Year 2022 Financial Results
-
Pharmanovia to Market GHRYVELIN™ (Macimorelin) in the European Economic Area (EEA) and UK as Diagnostic Test for Growth Hormone Deficiency (GHD)
-
Aeterna Zentaris Provides Business Update and Outlines Key Upcoming Milestones
-
JTC Team to Host the Virtual Investor 2023 Companies to Watch Event on January 17th, 18th, and 19th
-
Aeterna Zentaris to Present at the Virtual Investor 2023 Companies to Watch Event
-
Aeterna Zentaris Reports Third Quarter 2022 Financial Results
-
Aeterna Zentaris Reports Third Quarter 2022 Financial Results
-
Aeterna Zentaris Set to Regain Full Rights to Macrilen™ (Macimorelin) in U.S. and Canada from Novo Nordisk
-
Aeterna Zentaris Set to Regain Full Rights to Macrilen™ (Macimorelin) in U.S. and Canada from Novo Nordisk
-
Aeterna Zentaris Reports Second Quarter 2022 Financial Results and Recent Highlights
-
Aeterna Zentaris Reports Second Quarter 2022 Financial Results and Recent Highlights
-
Aeterna Zentaris Announces Effective Date of Share Consolidation
-
Aeterna Zentaris Announces Effective Date of Share Consolidation
-
Aeterna Zentaris Announces Shareholder Approval of Share Consolidation
-
Aeterna Zentaris Announces Shareholder Approval of Share Consolidation
-
Aeterna Zentaris Announces Further Adjournment of Shareholder Meeting
-
Aeterna Zentaris Announces Further Adjournment of Shareholder Meeting
-
Aeterna Zentaris Announces Results of Annual Meeting of Shareholders
-
Aeterna Zentaris Announces Results of Annual Meeting of Shareholders
-
Aeterna Zentaris Achieves Proof-of-Concept for the Treatment of NMOSD with AIM Biologicals Program
-
Aeterna Zentaris Achieves Proof-of-Concept for the Treatment of NMOSD with AIM Biologicals Program
-
Aeterna Zentaris to Present at the JMP Securities Life Sciences Conference
-
Aeterna Zentaris to Present at the JMP Securities Life Sciences Conference
-
Aeterna Zentaris’ Licensing Partner, Consilient Health Announces European Launch of Ghryvelin™ (macimorelin) for Diagnosing Adult Growth Hormone Deficiency
-
Aeterna Zentaris’ Licensing Partner, Consilient Health Announces European Launch of Ghryvelin™ (macimorelin) for Diagnosing Adult Growth Hormone Deficiency
-
Aeterna Zentaris to Present at the H.C. Wainwright Global Investment Conference
-
Aeterna Zentaris to Present at the H.C. Wainwright Global Investment Conference
-
Aeterna Zentaris Announces Virtual 2022 Meeting of Shareholders and Urges Shareholders to Vote in Favor of the Proposed Share Consolidation
-
Aeterna Zentaris Announces Virtual 2022 Meeting of Shareholders and Urges Shareholders to Vote in Favor of the Proposed Share Consolidation
-
Update on Positive Pre-Clinical Results from AIM Biologicals Development Program for the Potential Treatment of Parkinson’s Disease
-
Update on Positive Pre-Clinical Results from AIM Biologicals Development Program for the Potential Treatment of Parkinson’s Disease
-
Aeterna Zentaris Reports First Quarter 2022 Financial Results and Provides Business Outlook
-
Aeterna Zentaris Reports First Quarter 2022 Financial Results and Provides Business Outlook
-
Aeterna Zentaris Abstract Accepted for Presentation at IMMUNOLOGY2022™, the Annual Event of the American Association of Immunologists
Back to AEZS Stock Lookup
